An attenuated vaccine is a vaccine created by reducing the virulence of a pathogen, but still keeping it viable (or "live"). Attenuation takes an infectious agent and alters it so that it becomes harmless or less virulent. These vaccines contrast to those produced by "killing" the virus (inactivated vaccine).
Examples of live attenuated) vaccines include: Viral: measles vaccine, mumps vaccine, rubella vaccine and live attenuated influenza vaccine (the seasonal flu nasal spray and the 2009 H1N1 flu nasal spray), etc; Bacterial: BCG vaccine, oral typhoid vaccine and epidemic typhus vaccine.
In 2019, the market size of Live Attenuated Vaccines is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Live Attenuated Vaccines.
This report studies the global market size of Live Attenuated Vaccines, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Live Attenuated Vaccines sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
GlaxoSmithKline
Merck
Pfizer
Astellas Pharma
Johnson & Johnson
CSL
Sanofi
Serum Institute Of India
Market Segment by Product Type
Bacterial
Viral
Market Segment by Application
Hospitals
Clinics
Research Institutes
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Live Attenuated Vaccines status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Live Attenuated Vaccines manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Live Attenuated Vaccines are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Examples of live attenuated) vaccines include: Viral: measles vaccine, mumps vaccine, rubella vaccine and live attenuated influenza vaccine (the seasonal flu nasal spray and the 2009 H1N1 flu nasal spray), etc; Bacterial: BCG vaccine, oral typhoid vaccine and epidemic typhus vaccine.
In 2019, the market size of Live Attenuated Vaccines is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Live Attenuated Vaccines.
This report studies the global market size of Live Attenuated Vaccines, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Live Attenuated Vaccines sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
GlaxoSmithKline
Merck
Pfizer
Astellas Pharma
Johnson & Johnson
CSL
Sanofi
Serum Institute Of India
Market Segment by Product Type
Bacterial
Viral
Market Segment by Application
Hospitals
Clinics
Research Institutes
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Live Attenuated Vaccines status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Live Attenuated Vaccines manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Live Attenuated Vaccines are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global Live Attenuated Vaccines Market Size Growth Rate by Type (2019-2025)
1.3.2 Bacterial
1.3.3 Viral
1.4 Market Segment by Application
1.4.1 Global Live Attenuated Vaccines Market Share by Application (2019-2025)
1.4.2 Hospitals
1.4.3 Clinics
1.4.4 Research Institutes
1.4.5 Others
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Live Attenuated Vaccines Market Size
2.1.1 Global Live Attenuated Vaccines Revenue 2014-2025
2.1.2 Global Live Attenuated Vaccines Sales 2014-2025
2.2 Live Attenuated Vaccines Growth Rate by Regions
2.2.1 Global Live Attenuated Vaccines Sales by Regions 2014-2019
2.2.2 Global Live Attenuated Vaccines Revenue by Regions 2014-2019
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
3 Market Share by Manufacturers
3.1 Live Attenuated Vaccines Sales by Manufacturers
3.1.1 Live Attenuated Vaccines Sales by Manufacturers 2014-2019
3.1.2 Live Attenuated Vaccines Sales Market Share by Manufacturers 2014-2019
3.2 Revenue by Manufacturers
3.2.1 Live Attenuated Vaccines Revenue by Manufacturers (2014-2019)
3.2.2 Live Attenuated Vaccines Revenue Share by Manufacturers (2014-2019)
3.2.3 Global Live Attenuated Vaccines Market Concentration Ratio (CR5 and HHI)
3.3 Live Attenuated Vaccines Price by Manufacturers
3.4 Key Manufacturers Live Attenuated Vaccines Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into Live Attenuated Vaccines Market
3.6 Key Manufacturers Live Attenuated Vaccines Product Offered
3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 Bacterial Sales and Revenue (2014-2019)
4.1.2 Viral Sales and Revenue (2014-2019)
4.2 Global Live Attenuated Vaccines Sales Market Share by Type
4.3 Global Live Attenuated Vaccines Revenue Market Share by Type
4.4 Live Attenuated Vaccines Price by Type
5 Market Size by Application
5.1 Overview
5.2 Global Live Attenuated Vaccines Sales by Application
6 United States
6.1 United States Live Attenuated Vaccines Breakdown Data by Company
6.2 United States Live Attenuated Vaccines Breakdown Data by Type
6.3 United States Live Attenuated Vaccines Breakdown Data by Application
7 European Union
7.1 European Union Live Attenuated Vaccines Breakdown Data by Company
7.2 European Union Live Attenuated Vaccines Breakdown Data by Type
7.3 European Union Live Attenuated Vaccines Breakdown Data by Application
8 China
8.1 China Live Attenuated Vaccines Breakdown Data by Company
8.2 China Live Attenuated Vaccines Breakdown Data by Type
8.3 China Live Attenuated Vaccines Breakdown Data by Application
9 Rest of World
9.1 Rest of World Live Attenuated Vaccines Breakdown Data by Company
9.2 Rest of World Live Attenuated Vaccines Breakdown Data by Type
9.3 Rest of World Live Attenuated Vaccines Breakdown Data by Application
9.4 Rest of World Live Attenuated Vaccines Breakdown Data by Countries
9.4.1 Rest of World Live Attenuated Vaccines Sales by Countries
9.4.2 Rest of World Live Attenuated Vaccines Revenue by Countries
9.4.3 Japan
9.4.4 Korea
9.4.5 India
9.4.6 Southeast Asia
10 Company Profiles
10.1 GlaxoSmithKline
10.1.1 GlaxoSmithKline Company Details
10.1.2 Company Description and Business Overview
10.1.3 Sales, Revenue and Market Share of Live Attenuated Vaccines
10.1.4 Live Attenuated Vaccines Product Introduction
10.1.5 GlaxoSmithKline Recent Development
10.2 Merck
10.2.1 Merck Company Details
10.2.2 Company Description and Business Overview
10.2.3 Sales, Revenue and Market Share of Live Attenuated Vaccines
10.2.4 Live Attenuated Vaccines Product Introduction
10.2.5 Merck Recent Development
10.3 Pfizer
10.3.1 Pfizer Company Details
10.3.2 Company Description and Business Overview
10.3.3 Sales, Revenue and Market Share of Live Attenuated Vaccines
10.3.4 Live Attenuated Vaccines Product Introduction
10.3.5 Pfizer Recent Development
10.4 Astellas Pharma
10.4.1 Astellas Pharma Company Details
10.4.2 Company Description and Business Overview
10.4.3 Sales, Revenue and Market Share of Live Attenuated Vaccines
10.4.4 Live Attenuated Vaccines Product Introduction
10.4.5 Astellas Pharma Recent Development
10.5 Johnson & Johnson
10.5.1 Johnson & Johnson Company Details
10.5.2 Company Description and Business Overview
10.5.3 Sales, Revenue and Market Share of Live Attenuated Vaccines
10.5.4 Live Attenuated Vaccines Product Introduction
10.5.5 Johnson & Johnson Recent Development
10.6 CSL
10.6.1 CSL Company Details
10.6.2 Company Description and Business Overview
10.6.3 Sales, Revenue and Market Share of Live Attenuated Vaccines
10.6.4 Live Attenuated Vaccines Product Introduction
10.6.5 CSL Recent Development
10.7 Sanofi
10.7.1 Sanofi Company Details
10.7.2 Company Description and Business Overview
10.7.3 Sales, Revenue and Market Share of Live Attenuated Vaccines
10.7.4 Live Attenuated Vaccines Product Introduction
10.7.5 Sanofi Recent Development
10.8 Serum Institute Of India
10.8.1 Serum Institute Of India Company Details
10.8.2 Company Description and Business Overview
10.8.3 Sales, Revenue and Market Share of Live Attenuated Vaccines
10.8.4 Live Attenuated Vaccines Product Introduction
10.8.5 Serum Institute Of India Recent Development
11 Value Chain and Sales Channels Analysis
11.1 Value Chain Analysis
11.2 Sales Channels Analysis
11.2.1 Live Attenuated Vaccines Sales Channels
11.2.2 Live Attenuated Vaccines Distributors
11.3 Live Attenuated Vaccines Customers
12 Market Forecast
12.1 Global Live Attenuated Vaccines Sales and Revenue Forecast 2019-2025
12.2 Global Live Attenuated Vaccines Sales Forecast by Type
12.3 Global Live Attenuated Vaccines Sales Forecast by Application
12.4 Live Attenuated Vaccines Forecast by Regions
12.4.1 Global Live Attenuated Vaccines Sales Forecast by Regions 2019-2025
12.4.2 Global Live Attenuated Vaccines Revenue Forecast by Regions 2019-2025
12.5 United States Market Forecast
12.6 European Union Market Forecast
12.7 China Market Forecast
12.8 Rest of World
12.8.1 Japan
12.8.2 Korea
12.8.3 India
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
1 Report Overview
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global Live Attenuated Vaccines Market Size Growth Rate by Type (2019-2025)
1.3.2 Bacterial
1.3.3 Viral
1.4 Market Segment by Application
1.4.1 Global Live Attenuated Vaccines Market Share by Application (2019-2025)
1.4.2 Hospitals
1.4.3 Clinics
1.4.4 Research Institutes
1.4.5 Others
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Live Attenuated Vaccines Market Size
2.1.1 Global Live Attenuated Vaccines Revenue 2014-2025
2.1.2 Global Live Attenuated Vaccines Sales 2014-2025
2.2 Live Attenuated Vaccines Growth Rate by Regions
2.2.1 Global Live Attenuated Vaccines Sales by Regions 2014-2019
2.2.2 Global Live Attenuated Vaccines Revenue by Regions 2014-2019
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
3 Market Share by Manufacturers
3.1 Live Attenuated Vaccines Sales by Manufacturers
3.1.1 Live Attenuated Vaccines Sales by Manufacturers 2014-2019
3.1.2 Live Attenuated Vaccines Sales Market Share by Manufacturers 2014-2019
3.2 Revenue by Manufacturers
3.2.1 Live Attenuated Vaccines Revenue by Manufacturers (2014-2019)
3.2.2 Live Attenuated Vaccines Revenue Share by Manufacturers (2014-2019)
3.2.3 Global Live Attenuated Vaccines Market Concentration Ratio (CR5 and HHI)
3.3 Live Attenuated Vaccines Price by Manufacturers
3.4 Key Manufacturers Live Attenuated Vaccines Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into Live Attenuated Vaccines Market
3.6 Key Manufacturers Live Attenuated Vaccines Product Offered
3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 Bacterial Sales and Revenue (2014-2019)
4.1.2 Viral Sales and Revenue (2014-2019)
4.2 Global Live Attenuated Vaccines Sales Market Share by Type
4.3 Global Live Attenuated Vaccines Revenue Market Share by Type
4.4 Live Attenuated Vaccines Price by Type
5 Market Size by Application
5.1 Overview
5.2 Global Live Attenuated Vaccines Sales by Application
6 United States
6.1 United States Live Attenuated Vaccines Breakdown Data by Company
6.2 United States Live Attenuated Vaccines Breakdown Data by Type
6.3 United States Live Attenuated Vaccines Breakdown Data by Application
7 European Union
7.1 European Union Live Attenuated Vaccines Breakdown Data by Company
7.2 European Union Live Attenuated Vaccines Breakdown Data by Type
7.3 European Union Live Attenuated Vaccines Breakdown Data by Application
8 China
8.1 China Live Attenuated Vaccines Breakdown Data by Company
8.2 China Live Attenuated Vaccines Breakdown Data by Type
8.3 China Live Attenuated Vaccines Breakdown Data by Application
9 Rest of World
9.1 Rest of World Live Attenuated Vaccines Breakdown Data by Company
9.2 Rest of World Live Attenuated Vaccines Breakdown Data by Type
9.3 Rest of World Live Attenuated Vaccines Breakdown Data by Application
9.4 Rest of World Live Attenuated Vaccines Breakdown Data by Countries
9.4.1 Rest of World Live Attenuated Vaccines Sales by Countries
9.4.2 Rest of World Live Attenuated Vaccines Revenue by Countries
9.4.3 Japan
9.4.4 Korea
9.4.5 India
9.4.6 Southeast Asia
10 Company Profiles
10.1 GlaxoSmithKline
10.1.1 GlaxoSmithKline Company Details
10.1.2 Company Description and Business Overview
10.1.3 Sales, Revenue and Market Share of Live Attenuated Vaccines
10.1.4 Live Attenuated Vaccines Product Introduction
10.1.5 GlaxoSmithKline Recent Development
10.2 Merck
10.2.1 Merck Company Details
10.2.2 Company Description and Business Overview
10.2.3 Sales, Revenue and Market Share of Live Attenuated Vaccines
10.2.4 Live Attenuated Vaccines Product Introduction
10.2.5 Merck Recent Development
10.3 Pfizer
10.3.1 Pfizer Company Details
10.3.2 Company Description and Business Overview
10.3.3 Sales, Revenue and Market Share of Live Attenuated Vaccines
10.3.4 Live Attenuated Vaccines Product Introduction
10.3.5 Pfizer Recent Development
10.4 Astellas Pharma
10.4.1 Astellas Pharma Company Details
10.4.2 Company Description and Business Overview
10.4.3 Sales, Revenue and Market Share of Live Attenuated Vaccines
10.4.4 Live Attenuated Vaccines Product Introduction
10.4.5 Astellas Pharma Recent Development
10.5 Johnson & Johnson
10.5.1 Johnson & Johnson Company Details
10.5.2 Company Description and Business Overview
10.5.3 Sales, Revenue and Market Share of Live Attenuated Vaccines
10.5.4 Live Attenuated Vaccines Product Introduction
10.5.5 Johnson & Johnson Recent Development
10.6 CSL
10.6.1 CSL Company Details
10.6.2 Company Description and Business Overview
10.6.3 Sales, Revenue and Market Share of Live Attenuated Vaccines
10.6.4 Live Attenuated Vaccines Product Introduction
10.6.5 CSL Recent Development
10.7 Sanofi
10.7.1 Sanofi Company Details
10.7.2 Company Description and Business Overview
10.7.3 Sales, Revenue and Market Share of Live Attenuated Vaccines
10.7.4 Live Attenuated Vaccines Product Introduction
10.7.5 Sanofi Recent Development
10.8 Serum Institute Of India
10.8.1 Serum Institute Of India Company Details
10.8.2 Company Description and Business Overview
10.8.3 Sales, Revenue and Market Share of Live Attenuated Vaccines
10.8.4 Live Attenuated Vaccines Product Introduction
10.8.5 Serum Institute Of India Recent Development
11 Value Chain and Sales Channels Analysis
11.1 Value Chain Analysis
11.2 Sales Channels Analysis
11.2.1 Live Attenuated Vaccines Sales Channels
11.2.2 Live Attenuated Vaccines Distributors
11.3 Live Attenuated Vaccines Customers
12 Market Forecast
12.1 Global Live Attenuated Vaccines Sales and Revenue Forecast 2019-2025
12.2 Global Live Attenuated Vaccines Sales Forecast by Type
12.3 Global Live Attenuated Vaccines Sales Forecast by Application
12.4 Live Attenuated Vaccines Forecast by Regions
12.4.1 Global Live Attenuated Vaccines Sales Forecast by Regions 2019-2025
12.4.2 Global Live Attenuated Vaccines Revenue Forecast by Regions 2019-2025
12.5 United States Market Forecast
12.6 European Union Market Forecast
12.7 China Market Forecast
12.8 Rest of World
12.8.1 Japan
12.8.2 Korea
12.8.3 India
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
